Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8187
Reference
Drug alert 23/2024
Name
Drug Alert Class 3 Drug Alert 23 2024 – Class 3 medicines defect information – action within 5 days – Teva UK Ltd – GoResp Digihaler
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
Scotland
Drugs
Safety
Risks
Pharmaceutical Industry
Medicines Recall
Description
Teva UK Limited has informed the MHRA that it plans to withdraw from further sale all batches of GoResp Digihaler (budesonide and formoterol fumarate dihydrate) and the linked Digihaler App for commercial reasons. The inhalers containing the medicinal product are being withdrawn from the market because the App is no longer being supported, there is no product quality issue with the medicine itself.
From 1 June 2024 the Digihaler App described in the Patient Information Leaflet is no longer available for download from the Apple App Store and Google Play store. This means users will not be able to download the app, sign up, log in or load any new data.
This affects a very small number of patients who are currently using the App. However, the notification is being sent wider to ensure awareness and recall remaining stock.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2024-06-18 11:56:00
Click to go back to homepage